These ASOs effectively downregulated HIF-2α expression; however, they did not significantly impact tumor numbers and, in some cases, even aggravated liver fibrosis, highlighting the complexity of therapeutically targeting HIF-2α in HCC [86]. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.